35-75 MMOL OF MAGNESIUM BY SLOW I.V. INFUSION IN 5% GLUCOSE ON FIRST DAY FOLLOWED BY 25 MMOL DAILY UNTIL HYPOMAGNESAEMIA IS CORRECTED.
INTRAMUSCULAR: ADULTS AND OLDER CHILDREN: FOR SEVERE HYPOMAGNESEMIA, 1 TO 5 G (2 TO 10 ML OF 50% SOLUTION) DAILY IN DIVIDED DOSES; ADMINISTRATION IS REPEATED DAILY UNTIL SERUM LEVELS HAVE RETURNED TO NORMAL. IF DEFICIENCY IS NOT SEVERE, 1 G (2 ML OF 50% SOLUTION) CAN BE GIVEN ONCE OR TWICE DAILY.
PREVENTION OF SEIZURE RECURRENCE IN ECLAMPSIA, INITIALLY BY INTRAVENOUS INJECTION OVER 5-15 MINUTES, 4 G, FOLLOWED BY INTRAVENOUS INFUSION, 1 G/HOUR FOR AT LEAST 24 HOURS AFTER LAST SEIZURE; IF SEIZURE RECURS, ADDITIONAL DOSE BY INTRAVENOUS INJECTION, 2 G (4 G IF BODY-WEIGHT OVER 70 KG)
PREVENTION OF SEIZURES IN PRE-ECLAMPSIA [UNLICENSED INDICATION], INITIALLY BY INTRAVENOUS INFUSION OVER 5-15 MINUTES, 4 G FOLLOWED BY INTRAVENOUS INFUSION, 1 G/HOUR FOR 24 HOURS; IF SEIZURE OCCURS, ADDITIONAL DOSE BY INTRAVENOUS INJECTION, 2 G
INTRAVENOUS MAGNESIUM IS USED IN CORRECTING THE UNCOMMON VENTRICULAR TACHYCARDIA OF TORSADE DE POINTES. 1.2 TO 10 G OF INTRAVENOUS MAGNESIUM SULFATE IS ALSO A SAFE AND EFFECTIVE STRATEGY FOR THE ACUTE MANAGEMENT OF RAPID ATRIAL FIBRILLATION. ORAL MAGNESIUM SUPPLEMENTATION REDUCED THE FREQUENCY OF ASYMPTOMATIC VENTRICULAR ARRHYTHMIA IN PATIENTS WITH STABLE CONGESTIVE HEART FAILURE SECONDARY TO CORONARY ARTERY DISEASE.
INTRAVENOUS ADMINISTRATION :
FOR INTRAVENOUS INJECTION CONCENTRATION OF MAGNESIUM SULPHATE SHOULD NOT EXCEED 20% (DILUTE 1 PART OF MAGNESIUM SULPHATE INJECTION 50% WITH AT LEAST 1.5 PARTS OF WATER FOR INJECTIONS) .